Evaluating the 10-Year Impact of an Immunoglobulin Utilization Management and Dose Optimization Program in the Managed Care Setting 

Authors: ​A. Liang, PharmD; E. Ventura, PharmD; B. MacDonald, PharmD; J. Almazan, PharmD, AAHIVE, BCGP; H. Makanji, PharmD.​
The recipient of a gold award, this study analyzed the impact of immunoglobulin dose optimization programs in a managed care setting.
 

Impact of a Pharmacist-Facing Clinical Management Tool: Identification and Management of Cumulative Oversupply in Pharmacy Benefit Dupilumab Utilizers 
Authors: ​N. Friedlander, PharmD; K.L. Curtis, PharmD; P.P. Gleason, PharmD.​
This study analyzed managed care pharmacist outreach through Prime’s HighTouchRx product to reduce drug therapy cost of the inflammation drug dupilumab (Dupixent).

Dosage Form and Product Strength Optimization: Containing the Cost of Ibrutinib Therapy Through a Pharmacist-Facing Clinical Management Tool  
Authors: ​N. Friedlander, PharmD; K.L. Curtis, PharmD; P.P. Gleason, PharmD.​
This study evaluated the effectiveness of Prime’s HighTouchRx product for improving cost containment associated of ibrutinib (Imbruvica) for oral oncology therapy.

Real-World Extended Dosing Assessment for Eye(s) New to Faricimab-svoa Therapy 
Authors: E. Eckwright, PharmD; S. Thunselle PharmD; P.P. Gleason, PharmD.​
This study assessed extended dosing of faricimab-svoa (Vabysmo) therapy for retinal diseases. 
 
Methodological Framework for Propensity Adjusted Benchmarks for Pharmacy Key Performance Indicators 
Authors: ​B. Hunter, MS; K. Brown-Gentry, MS; J. Scripture, MS, PhD; D. Eckwright, PharmD; K. Prasla, PharmD, PhD.​
The purpose of the study was to create a methodological framework for using propensity score weighting to adjust for varying risk profiles when comparing an index group to a benchmark group with a similar risk profile on pharmacy key performance indicators.

Promoting Health Equity Through Enhanced, Personalized Digital Outreach
Authors: ​N. Grevenitz, PharmD; S. Makanji, PharmD; M. Santilli, PharmD; V. Bisceglio, B.S.; M. DiMaio, PharmD.
This study focuses on how translation services can improve health equity for Medicare members. 
 
Real-World Adherence and Persistence to Glucagon-Like Peptide-1 Receptor Agonists at Two Years among Non-Diabetic Obese Commercially Insured Adults 
Authors: ​​L.Z. Marshall, PharmD, Ph.D.; Y. Qiu, MS; B.Y. Urick, PharmD, Ph.D.; N. Friedlander, PharmD; R.S. Leslie, Ph.D.; P.P. Gleason, PharmD.
The recipient of a silver award, this study is part of Prime Therapeutics’ ongoing real-world study of individuals who newly started GLP-1 drugs for weight loss.

Real-World Case Series Study of Spinal Muscular Atrophy Pediatric Patients Treated with Onasemnogene Abeparvovec (Zolgensma) 
​Authors: R.S. Leslie, MPH, Ph.D; L.Z. Marshall, PharmD, Ph.D; P.P. Gleason, PharmD.​
The recipient of a silver award, this study researched real-world spinal muscular atrophy Zolgensma gene therapy treatment outcomes.

Leveraging Publicly Available SDOH Measures to Segment Members and Quantify Differences in Diabetic Medication Adherence: A Latent Profile Analysis 
​Authors: J. Scripture, MS, PhD; K. Brown-Gentry, MS; K. Prasla, PharmD, PhD.​
This study looked at patterns in ZIP codes across the United States and SDOH measures to identify medication adherence for patients with diabetes.

Unlocking Public Health Insights: Leveraging Air Quality Data to Develop Social Determinants of Health Metrics Linked to Asthma Medication Ratio 
​Authors: K. Brown-Gentry, MS; B. Hunter, MS; J. Scripture, MS, PhD; K. Prasla, PharmD, PhD; M. Santilli, PharmD.
​​​​​​​This study explored how researchers can use SDOH measures to evaluate the treatment of asthma among affected populations.

All brand names are property of their respective owners.